Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. This development is important because it expands the trial's geographic reach and potentially accelerates enrollment of a genetically defined patient population that has limited treatment options. The lead Taiwan site is now open to accrual and actively screening patients, with two additional sites anticipated to receive IRB approval in the fourth quarter. In the United States, a central IRB has already approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation.
The trial's focus on the L858R mutation is strategic. Patients with this mutation often develop resistance to tyrosine kinase inhibitors, and LP-300 is being tested in combination with carboplatin and pemetrexed to overcome that resistance. The amended protocol allows LP-300 to be administered for up to eight cycles, up from six previously. Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company cautions that these findings are preliminary, exploratory, and based on small patient numbers, the results suggest a potential clinical benefit that warrants further investigation.
The implications of this announcement extend beyond the trial itself. Lantern's proprietary RADR artificial intelligence and machine-learning platform is designed to transform the cost, pace, and precision of oncology drug development by identifying patients most likely to benefit from its therapies. The HARMONIC trial serves as a proof point for this biomarker-driven approach. If successful, it could validate RADR's ability to streamline drug development and reduce the time and expense of bringing new cancer treatments to market. For investors, the progress in Taiwan and the U.S. signals that Lantern is executing on its clinical strategy and could generate meaningful data in the near term.
For more details, the full press release is available at https://ibn.fm/CqeDR. The latest news and updates relating to LTRN can be found in the company's newsroom at https://ibn.fm/LTRN. BioMedWire (BMW), a specialized communications platform for the biotech and life sciences sectors, is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and editorial syndication to 5,000+ outlets, among other services. These platforms help companies like Lantern Pharma reach a wide audience of investors and journalists.
